戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 the medical treatment of AIP-dependent human acromegaly.
2 rrent mutation in GPR101 in some adults with acromegaly.
3 de) in patients with inadequately controlled acromegaly.
4 cated gene in samples from 248 patients with acromegaly.
5 ress growth hormone (GH) secretion and treat acromegaly.
6 tion result in hyperglycaemia in patients of acromegaly.
7 alogs provide safe and effective therapy for acromegaly.
8 evelop skeletal abnormalities reminiscent of acromegaly.
9  a patient with McCune-Albright syndrome and acromegaly.
10 ing tumors; it is less commonly required for acromegaly.
11 owth disorders such as cancer, diabetes, and acromegaly.
12 en implicated in proteinuria in diabetes and acromegaly.
13  recommendations on therapeutic outcomes for acromegaly.
14 s mellitus that are suited for patients with acromegaly.
15                    Twenty patients of active acromegaly (10 each, with and without diabetes) underwen
16 FPA) and ATR-FTIR spectral acquisition of 16 acromegaly, 18 Cushing's, and 22 NFPA patient's serum sa
17 etabolomics fingerprint, Raman spectra of 16 acromegaly, 19 Cushing's, and 33 nonfunctional PA (NFPA)
18  GH-secreting pituitary adenoma and leads to acromegaly - a disorder of disproportionate skeletal, ti
19 risk of fractures in individuals with GHD or acromegaly, a condition of GH excess.
20                                          For acromegaly and adrenocorticotropin hormone (ACTH)-secret
21 (hGHR) prescribed for treating patients with acromegaly and discovered in our laboratory almost 3 dec
22 d managing growth-related disorders, such as acromegaly and growth hormone deficiency.
23 of thyroid dysfunction, hyperparathyroidism, acromegaly and hypercortisolism on bone.
24 ochemical remission rates currently seen for acromegaly and illustrate the relevance of advanced intr
25 ese issues will lead to better management of acromegaly and its associated metabolic complications.
26 derlying mechanisms for diabetes mellitus in acromegaly and its effect on morbidity and mortality.
27 reotide was first used for the management of acromegaly and later used for metastatic gastroenteropan
28 like headache was only seen in patients with acromegaly and prolactinoma.
29  Carney complex and, most recently, familial acromegaly and prolactinomas and other tumors caused by
30 ildren treated with GH, and tall stature and acromegaly are associated with an increased incidence of
31 management of diabetes mellitus secondary to acromegaly are lacking due to limited research on this s
32  adults; the genetic causes of gigantism and acromegaly are poorly understood.
33              Somatostatin analogues improved acromegaly-associated headache in 64% of cases, although
34                                    To detect acromegaly cases from the general target population, fou
35        We tested four algorithms to identify acromegaly cases using claims databases with high sensit
36  growth hormone excess causing gigantism and acromegaly, clinically non-functioning adenomas, and the
37                                     The 15th Acromegaly Consensus Conference in September 2023 update
38                           Many patients with acromegaly do not achieve biochemical control despite re
39 lated growth hormone (GH) hypersecretion and acromegaly; however, regulatory mechanisms that promote
40 ased on the presence of claims suggestive of acromegaly in >= 2 different databases (i.e., hospital d
41 ve percent are somatotropinomas, which cause acromegaly in adults and gigantism in children, and 4% a
42 h hormone leads to gigantism in children and acromegaly in adults; the genetic causes of gigantism an
43 n this Primer, we review the main aspects of acromegaly, including scientific advances that underlie
44 otroph adenoma GH secretion in patients with acromegaly, inhibited cAMP and GH and reversed DNA damag
45  equipoise insulin resistance in patients of acromegaly irrespective of their glycaemic status.
46                                  Patients of acromegaly, irrespective of presence or absence of hyper
47                                              Acromegaly is a human disease of growth hormone (GH) exc
48                                              Acromegaly is a rare disabling disorder that results in
49                                              Acromegaly is a rare disease characterized by an excessi
50                                              Acromegaly is a rare endocrine disease caused by hyperse
51                                              Acromegaly is a unique human model, where insulin resist
52           Diabetes mellitus in patients with acromegaly is associated with an increased risk of cardi
53                Growth hormone (GH) excess in acromegaly is associated with increased precancerous col
54                                              Acromegaly is characterized by increased release of grow
55             The risk of diabetes mellitus in acromegaly is driven by increased exposure to growth hor
56 endations highlighting how an evidence-based acromegaly management algorithm could be optimized in cl
57 iabetes mellitus is a common complication of acromegaly, occurring in approximately one-third of pati
58 ver, the effects of the treatment of GHD and acromegaly on locally produced IGF1 and IGF binding prot
59 ffect of interventions used to treat GHD and acromegaly on the skeleton is variable and dependent on
60 be particularly challenging in patients with acromegaly or Cushing's disease.
61 e highlight clinical data from patients with acromegaly or GHD, alongside data from cellular and anim
62 hypertrophy due to valvular aortic stenosis, acromegaly, or growth hormone deficiency, conditions ass
63 dies have reported an increased incidence of acromegaly owing to better disease awareness, improved d
64                        This Review discusses acromegaly pathogenesis and management options.
65 nistration of a GH receptor (GHR) blocker in acromegaly patients induced colon p53 and adenomatous po
66                     Medial wall resection in acromegaly resulted in the highest potential for biochem
67  to pituitary adenoma, seen in patients with acromegaly, results in severe arthropathies.
68       Fifty-two experts in the management of acromegaly reviewed the current literature and assessed
69 ments will reduce mortality in patients with acromegaly to levels in the general population.
70                                              Acromegaly treatment approaches, which include surgery,
71  coding algorithms for the identification of acromegaly using Italian claims databases.
72 n and cardiac myxomas, Cushing syndrome, and acromegaly were present in 62, 30, 31 and 8 percent of t
73 ituitary-directed treatment in patients with acromegaly who are inadequately controlled using first-g
74 ligible patients aged 18 years or older with acromegaly who were inadequately controlled (5-point, 2
75 be the first-line treatment in patients with acromegaly who will not benefit from or are not suitable
76 eveloped, Raman spectral analysis classified acromegaly with an accuracy of 79.17%, sensitivity of 75
77        ATR-FTIR spectral analysis classified acromegaly with an accuracy of 95.83%, sensitivity of 10
78 utation (p.E308D) in 11 of 248 patients with acromegaly, with the mutation found mostly in tumors.